Reviva Pharmaceuticals Holdings Stock Buy Hold or Sell Recommendation
| RVPHW Stock | USD 0.06 0 5.77% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Reviva Pharmaceuticals Holdings is 'Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Reviva Pharmaceuticals Holdings given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Reviva Pharmaceuticals Holdings, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Reviva Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Reviva and provide practical buy, sell, or hold advice based on investors' constraints. Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Reviva |
Execute Reviva Pharmaceuticals Buy or Sell Advice
The Reviva recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Reviva Pharmaceuticals Holdings. Macroaxis does not own or have any residual interests in Reviva Pharmaceuticals Holdings or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Reviva Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Reviva Pharmaceuticals Trading Alerts and Improvement Suggestions
| Reviva Pharmaceuticals generated a negative expected return over the last 90 days | |
| Reviva Pharmaceuticals has high historical volatility and very poor performance | |
| Reviva Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Reviva Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Reviva Pharmaceuticals Holdings has accumulated 17.98 M in total debt. Reviva Pharmaceuticals has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about Reviva Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Reviva Pharmaceuticals Holdings has accumulated about 353.26 K in cash with (28.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Reviva Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Saxena Parag of 5300 shares of Reviva Pharmaceuticals at 3.78 subject to Rule 16b-3 |
Reviva Pharmaceuticals current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Reviva analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Reviva analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Reviva Pharmaceuticals Returns Distribution Density
The distribution of Reviva Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Reviva Pharmaceuticals' future price movements. The chart of the probability distribution of Reviva Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Reviva Pharmaceuticals Holdings price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Reviva Pharmaceuticals returns is essential to provide solid investment advice for Reviva Pharmaceuticals.
| Mean Return | -0.04 | Value At Risk | -24.32 | Potential Upside | 28.57 | Standard Deviation | 20.46 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Reviva Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Reviva Pharmaceuticals Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 8.8M | 20.9M | (11.2M) | 4.8M | 4.4M | 3.7M | |
| Free Cash Flow | (3.7M) | (10.7M) | (19.0M) | (28.3M) | (25.5M) | (24.2M) | |
| Change In Working Capital | (2.3M) | (702.2K) | 5.0M | 7.3M | 8.4M | 8.8M | |
| Begin Period Cash Flow | 193.0 | 8.8M | 29.7M | 18.5M | 21.3M | 12.6M | |
| Other Cashflows From Financing Activities | 12.8M | 98.5K | 19.0K | 5.7M | 5.1M | 3.0M | |
| Other Non Cash Items | 2.4M | (1.6M) | 194.7K | 239.2K | 215.3K | 202.1K | |
| Total Cash From Operating Activities | (3.7M) | (10.7M) | (19.0M) | (28.3M) | (25.5M) | (24.2M) | |
| Net Income | (3.8M) | (8.5M) | (24.3M) | (39.3M) | (35.3M) | (33.6M) | |
| Total Cash From Financing Activities | 12.8M | 31.6M | 7.8M | 33.2M | 38.1M | 40.1M | |
| End Period Cash Flow | 8.8M | 29.7M | 18.5M | 23.4M | 26.9M | 17.7M |
Reviva Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Reviva Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Reviva Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Reviva stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.24 | |
β | Beta against Dow Jones | 2.70 | |
σ | Overall volatility | 18.44 | |
Ir | Information ratio | 0 |
Reviva Pharmaceuticals Volatility Alert
Reviva Pharmaceuticals Holdings is displaying above-average volatility over the selected time horizon. Reviva Pharmaceuticals Holdings is a penny stock. Although Reviva Pharmaceuticals may be in fact a good investment, many penny stocks are subject to artificial price hype. Make sure you completely understand the upside potential and downside risk of investing in Reviva Pharmaceuticals Holdings. We encourage investors to look for signals such as message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on Reviva instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Reviva Pharmaceuticals Fundamentals Vs Peers
Comparing Reviva Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Reviva Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Reviva Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Reviva Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Reviva Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Reviva Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Reviva Pharmaceuticals to competition |
| Fundamentals | Reviva Pharmaceuticals | Peer Average |
| Return On Equity | -17.95 | -0.31 |
| Return On Asset | -3.28 | -0.14 |
| Number Of Shares Shorted | 3.62 K | 4.71 M |
| EBITDA | (39.5 T) | 3.9 B |
| Net Income | (39.26 M) | 570.98 M |
| Cash And Equivalents | 353.26 K | 2.7 B |
| Cash Per Share | 0.02 X | 5.01 X |
| Total Debt | 17.98 M | 5.32 B |
| Current Ratio | 0.03 X | 2.16 X |
| Book Value Per Share | (0.30) X | 1.93 K |
| Cash Flow From Operations | (28.32 M) | 971.22 M |
| Number Of Employees | 15 | 18.84 K |
| Beta | -0.099 | -0.15 |
| Market Capitalization | 85.81 M | 19.03 B |
| Total Asset | 23.7 M | 29.47 B |
| Retained Earnings | (134.35 M) | 9.33 B |
| Working Capital | 6.53 M | 1.48 B |
| Net Asset | 23.7 M |
Note: Acquisition by Saxena Parag of 5300 shares of Reviva Pharmaceuticals at 3.78 subject to Rule 16b-3 [view details]
Reviva Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Reviva . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Reviva Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Reviva Pharmaceuticals Holdings? Buying financial instruments such as Reviva Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Reviva Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Processed Foods Thematic Idea Now
Processed Foods
Companies producing and distributing processed foods to retail sectors. The Processed Foods theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Processed Foods Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Reviva Stock Analysis
When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.